Developing new medications for opioid use disorders
Development of Next-generation Pharmacotherapy for Opioid Use Disorders
This study is working on a new medication to help people with opioid addiction by targeting a specific receptor in the brain, aiming to reduce the need for oxycodone without the negative side effects of current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Astraea Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Mountain View, United States) |
| Project ID | NIH-10909978 on NIH RePORTER |
What this research studies
This research focuses on creating a new type of medication aimed at treating opioid use disorders (OUD) by targeting the nociceptin opioid receptor. The approach involves developing small-molecule compounds that have shown promise in reducing the intake of oxycodone in animal models without the harmful side effects associated with current treatments like methadone and buprenorphine. The goal is to provide a safer alternative that does not lead to physical dependence or respiratory depression, making it a potentially effective option for individuals struggling with opioid addiction.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from opioid use disorders who are seeking alternative treatment options.
Not a fit: Patients who are not struggling with opioid use disorders or those who have not responded to previous treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new medication that effectively treats opioid addiction without the risks of dependence and overdose.
How similar studies have performed: While this approach is innovative, previous research has shown promise in targeting the nociceptin receptor, indicating potential for success in this area.
Where this research is happening
Mountain View, United States
- Astraea Therapeutics, LLC — Mountain View, United States (Active)
Researchers
- Principal investigator: Zaveri, Nurulain T — Astraea Therapeutics, LLC
- Study coordinator: Zaveri, Nurulain T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.